epcoritamab + rituximab + cytarabine + dexamethasone + oxaliplatin + carboplatin

This is a **combination treatment regimen** consisting of: - **Epcoritamab**, a subcutaneous bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, acting as a T-cell engager to promote selective cytotoxicity of malignant B cells. - **Rituximab**, a chimeric anti-CD20 monoclonal antibody, causing B-cell depletion by triggering apoptosis and immune-mediated cytotoxicity. - **Cytarabine**, a small molecule antimetabolite and nucleoside analog, inhibiting DNA synthesis in rapidly dividing cells. - **Dexamethasone**, a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressant effects. - **Oxaliplatin**, a platinum-based chemotherapeutic that induces DNA crosslinking and inhibits DNA replication. - **Carboplatin**, another platinum-based alkylating agent, causing DNA damage and cell death in cancer cells. This combination aims to treat advanced and aggressive hematologic malignancies (e.g., relapsed/refractory non-Hodgkin lymphoma), leveraging synergistic effects of immunotherapy and multi-agent chemotherapy. Epcoritamab and rituximab both target CD20 but by different mechanisms, with epcoritamab engaging T cells for bispecific cytotoxicity, while rituximab drives antibody-dependent cellular cytotoxicity, complement-mediated cytotoxicity, and direct apoptosis. Cytarabine, dexamethasone, oxaliplatin, and carboplatin each contribute to antitumor activity through distinct cytotoxic or immunosuppressive mechanisms, broadening the combination's potential efficacy against aggressive lymphoid malignancies[5][2]. Such regimens may be under investigation in advanced relapsed/refractory lymphoma settings.

Brand names

epcoritamab: Epkinlyrituximab: Rituxan, Mabthera, Riabni, Ruxience, Truximacytarabine: Cytosar-U, DepoCytdexamethasone: Decadron, DexPakoxaliplatin: Eloxatincarboplatin: Paraplatin